| 2022-10-05 |
复牌提示：
2022-10-04 19:52:01 停牌，复牌日期 2022-10-06 00:00:01
|
| 2022-08-29 |
股东大会：
将于2022-09-30召开股东大会
会议内容 ▼▲
- 1.To consider and vote on the proposal to adopt the Agreement and Plan of Merger, dated as of August 7, 2022 (as it may be amended from time to time, which we refer to as the “Merger Agreement”), by and among Pfizer Inc., a Delaware corporation (which we refer to as “Parent” or “Pfizer”), Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (which we refer to as “Merger Sub”), and GBT. Pursuant to the terms of the Merger Agreement, subject to the terms and conditions set forth therein, Merger Sub will merge with and into GBT (which we refer to as the “Merger”), with GBT continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent (which we refer to as the “Merger Agreement Proposal”);
2.To consider and vote on the proposal to approve, on an advisory (nonbinding) basis, the compensation that may be paid or become payable to GBT’s named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement (which we refer to as the “Compensation Proposal”);
3.To consider and vote on any proposal to adjourn the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting (which we refer to as the “Adjournment Proposal”).
|
| 2022-08-29 |
详情>>
股本变动：
变动后总股本6747.62万股
|
| 2022-08-08 |
详情>>
业绩披露：
2022年中报每股收益-2.51美元,归母净利润-1.64亿美元,同比去年增长-13.4%
|
| 2022-08-08 |
财报披露：
美东时间 2022-08-08 盘后发布财报
|
| 2022-05-04 |
详情>>
业绩披露：
2022年一季报每股收益-1.26美元,归母净利润-8142.3万美元,同比去年增长-8.67%
|
| 2022-04-28 |
股东大会：
将于2022-06-14召开股东大会
会议内容 ▼▲
- 1.to elect the three Class I directors, as nominated by our Board of Directors, to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.to approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3.to ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022;
4.to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-02-23 |
详情>>
业绩披露：
2019年年报每股收益-4.57美元,归母净利润-2.67亿美元,同比去年增长-53.14%
|
| 2022-02-23 |
详情>>
业绩披露：
2021年年报每股收益-4.81美元,归母净利润-3.03亿美元,同比去年增长-22.43%
|
| 2021-11-04 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-3.45美元,归母净利润-2.16亿美元,同比去年增长-16.02%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-03 |
详情>>
业绩披露：
2021年中报每股收益-2.32美元,归母净利润-1.45亿美元,同比去年增长-14.82%
|
| 2021-05-05 |
详情>>
业绩披露：
2021年一季报每股收益-1.21美元,归母净利润-7493万美元,同比去年增长-2.61%
|
| 2021-04-28 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.to elect the three Class III directors, as nominated by our Board of Directors, to hold office until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.to approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3.to ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021;
4.to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-02-24 |
详情>>
业绩披露：
2020年年报每股收益-4.04美元,归母净利润-2.48亿美元,同比去年增长7.20%
|
| 2020-11-05 |
详情>>
业绩披露：
2020年三季报(累计)每股收益-3.04美元,归母净利润-1.86亿美元,同比去年增长-8.76%
|
| 2020-08-05 |
详情>>
业绩披露：
2020年中报每股收益-2.06美元,归母净利润-1.26亿美元,同比去年增长-18.47%
|
| 2020-04-28 |
股东大会：
将于2020-06-17召开股东大会
会议内容 ▼▲
- 1.to elect the three Class II directors, as nominated by the Board of Directors, to hold office until the 2023 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.to approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3.to ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020;
4.to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-04-29 |
股东大会：
将于2019-06-18召开股东大会
会议内容 ▼▲
- 1.to elect the three Class I directors, as nominated by the Board of Directors, to hold office until the 2022 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.to approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3.to ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2019;
4.to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2018-07-06 |
详情>>
内部人交易：
Calhoun Lesley Ann等共交易9笔
|
| 2018-04-26 |
股东大会：
将于2018-06-20召开股东大会
会议内容 ▼▲
- 1.to elect the three Class III directors, as nominated by the Board of Directors, to hold office until the 2021 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2.to approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3.to recommend, on a non-binding, advisory basis, the preferred frequency of future advisory votes on the compensation of our named executive officers;
4.to ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018;
5.to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-28 |
股东大会：
将于2017-06-20召开股东大会
会议内容 ▼▲
- 1. To elect two (2) Class II directors, as nominated by the Company’s Board of Directors (“Board of Directors”), to hold office until the 2020 Annual Meeting of Stockholders or until their successors are duly elected and qualified;
2. To ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2017;
3. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2016-04-28 |
股东大会：
将于2016-06-16召开股东大会
会议内容 ▼▲
- 1. To elect the three Class I directors, as nominated by the Board of Directors, to hold office until the 2019 Annual Meeting of Stockholders or until their successors are duly elected and qualified.
2. To ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016.
3. To ratify the Company's 2015 Stock Option and Incentive Plan.
4. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|